Rhenman & Partners Asset Management Ab Intra Cellular Therapies, Inc. Transaction History

Rhenman & Partners Asset Management Ab

$959 Million
Q4 2024

A detailed history of Rhenman & Partners Asset Management Ab transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 176,000 shares of ITCI stock, worth $23.1 Million. This represents 1.53% of its overall portfolio holdings.

Number of Shares

176,000

Previous 205,500 14.36%

Holding current value

$23.1 Million

Previous $15 Million 2.18%

% of portfolio

1.53%

Previous 1.25%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$71.19 - $91.57 $2.1 Million - $2.7 Million	-29,500 Reduced 14.36%	176,000 $14.7 Million
Q3 2024 Nov 13, 2024	BUY	$67.99 - $80.84 $4.32 Million - $5.13 Million	63,500 Added 44.72%	205,500 $15 Million
Q2 2024 Aug 13, 2024	BUY	$64.76 - $79.84 $291,420 - $359,280	4,500 Added 3.27%	142,000 $9.73 Million
Q1 2024 May 14, 2024	BUY	$64.37 - $75.65 $3.06 Million - $3.59 Million	47,500 Added 52.78%	137,500 $9.52 Million
Q4 2023 Feb 13, 2024	SELL	$46.37 - $73.65 $231,850 - $368,250	-5,000 Reduced 5.26%	90,000 $6.45 Million
Q3 2023 Nov 13, 2023	BUY	$52.09 - $64.1 $2.5 Million - $3.08 Million	48,000 Added 102.13%	95,000 $4.95 Million
Q3 2023 Nov 09, 2023	SELL	$52.09 - $64.1 $2.5 Million - $3.08 Million	-48,000 Reduced 50.53%	47,000 $2.45 Million
Q2 2023 Aug 11, 2023	SELL	$54.67 - $66.44 $546,700 - $664,400	-10,000 Reduced 9.52%	95,000 $6.02 Million
Q1 2023 May 11, 2023	SELL	$43.8 - $56.99 $876,000 - $1.14 Million	-20,000 Reduced 16.0%	105,000 $5.69 Million
Q3 2022 Nov 14, 2022	SELL	$42.7 - $59.99 $640,500 - $899,850	-15,000 Reduced 10.71%	125,000 $5.71 Million
Q2 2022 Aug 12, 2022	SELL	$43.0 - $65.64 $6.02 Million - $9.19 Million	-140,000 Reduced 50.0%	140,000 $7.99 Million
Q1 2022 May 13, 2022	SELL	$38.74 - $62.09 $4.26 Million - $6.83 Million	-110,000 Reduced 28.21%	280,000 $17.1 Million
Q4 2021 Feb 11, 2022	SELL	$35.2 - $53.42 $1.4 Million - $2.12 Million	-39,728 Reduced 9.24%	390,000 $20.3 Million
Q2 2021 Aug 13, 2021	SELL	$29.3 - $44.5 $821,865 - $1.25 Million	-28,050 Reduced 6.13%	429,728 $17.5 Million
Q1 2021 May 14, 2021	SELL	$30.8 - $39.51 $1.3 Million - $1.67 Million	-42,222 Reduced 8.44%	457,778 $15.5 Million
Q4 2020 Jan 19, 2021	BUY	$23.34 - $32.22 $583,500 - $805,500	25,000 Added 5.26%	500,000 $15.9 Million
Q2 2020 Jul 16, 2020	SELL	$14.35 - $26.64 $1.33 Million - $2.47 Million	-92,534 Reduced 16.3%	475,000 $12.2 Million
Q1 2020 Apr 16, 2020	BUY	$12.31 - $33.12 $831,343 - $2.24 Million	67,534 Added 13.51%	567,534 $8.72 Million
Q4 2019 Jan 17, 2020	SELL	$7.26 - $38.49 $2.54 Million - $13.5 Million	-350,000 Reduced 41.18%	500,000 $17.2 Million
Q3 2019 Oct 16, 2019	SELL	$7.47 - $14.03 $745,752 - $1.4 Million	-99,833 Reduced 10.51%	850,000 $6.35 Million
Q1 2019 Apr 11, 2019	BUY	$10.9 - $14.09 $3.16 Million - $4.08 Million	289,851 Added 43.92%	949,833 $11.6 Million
Q4 2018 Feb 05, 2019	BUY	$10.36 - $20.96 $51,800 - $104,800	5,000 Added 0.76%	659,982 $7.52 Million
Q3 2018 Oct 03, 2018	SELL	$17.77 - $22.9 $745,895 - $961,227	-41,975 Reduced 6.02%	654,982 $14.2 Million
Q2 2018 Jul 20, 2018	SELL	$17.33 - $23.4 $1.66 Million - $2.24 Million	-95,773 Reduced 12.08%	696,957 $12.3 Million
Q1 2018 Apr 11, 2018	SELL	$15.16 - $25.49 $4.42 Million - $7.44 Million	-291,851 Reduced 26.91%	792,730 $16.7 Million
Q4 2017 Jan 19, 2018	SELL	$14.27 - $16.79 $1.36 Million - $1.6 Million	-95,319 Reduced 8.08%	1,084,581 $15.7 Million
Q3 2017 Oct 13, 2017	BUY	$10.77 - $22.1 $12.7 Million - $26.1 Million	1,179,900	1,179,900 $18.6 Million

Others Institutions Holding ITCI

# of Institutions

419

Shares Held

88.8M

Call Options Held

284K

Put Options Held

105K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12.4B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account

Rhenman & Partners Asset Management Ab Intra Cellular Therapies, Inc. Transaction History